{
    "clinical_study": {
        "@rank": "68973", 
        "arm_group": [
            {
                "arm_group_label": "Apo-Oxycodone CR\u00ae", 
                "arm_group_type": "Active Comparator", 
                "description": "a single 40mg oral dose of the controlled release oxycodone formulation Apo-Oxycodone CR\u00ae"
            }, 
            {
                "arm_group_label": "OxyNEO\u00ae", 
                "arm_group_type": "Active Comparator", 
                "description": "a single 40mg oral dose of the controlled release oxycodone formulation OxyNEO\u00ae"
            }, 
            {
                "arm_group_label": "OxyContin\u00ae", 
                "arm_group_type": "Active Comparator", 
                "description": "a single 40mg oral dose of the controlled release oxycodone formulation OxyContin\u00ae"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "a single oral dose of placebo prepared using gelatin capsules and lactose filler with identical looking study capsules as the oxycodone products"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this study is to examine the abuse liability of a single 40mg dose of 3\n      controlled release oxycodone formulations (Apo-Oxycodone CR\u00ae, OxyNEO\u00ae, and the original\n      OxyContin\u00ae) in non-dependent recreational opioid users by assessing the self-reported acute\n      effects of the drugs and taking blood samples to measure drug concentrations. The\n      investigators think there may be differences in how well these drugs are liked when\n      swallowed whole due to differences in how the products are formulated."
        }, 
        "brief_title": "Abuse Liability of Controlled-Release Oxycodone Formulations", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Substance-Related Disorders", 
        "condition_browse": {
            "mesh_term": "Substance-Related Disorders"
        }, 
        "detailed_description": {
            "textblock": "This is a single-center, single-dose, semi-double-blind, placebo-controlled, randomized,\n      crossover, abuse liability study to be conducted in healthy subjects who are non-dependent\n      recreational opioid users. The study will consist of 4 study days during which each subject\n      will take one tablet of either 40mg OxyContin\u00ae, 40mg OxyNEO\u00ae, 40mg Apo-Oxycodone CR\u00ae or\n      placebo. The participants will be assessed for both pharmacokinetic and pharmacodynamic\n      outcomes."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male and female subjects 18 to 50 years of age\n\n          -  Willing and capable to give written informed consent\n\n          -  Subjects must have used opioids recreationally to achieve a \"high\" on at least five\n             occasions in the 12 months before screening and at least once in the 90 days before\n             screening according to self-report\n\n          -  Females of childbearing potential have to use a medically acceptable form of birth\n             control and have a negative pregnancy test\n\n          -  Pass medical assessment, which includes physical examination, assessment of medical\n             history, vital signs, blood work, and urine toxicology screen\n\n          -  Willing to abstain from alcohol 12 hours before and during the study days\n\n        Exclusion Criteria:\n\n          -  Current or past Axis I psychiatric illness (including current drug dependence or past\n             opioid dependence, except nicotine dependence)\n\n          -  Current hepatic disease or renal failure\n\n          -  Pregnancy or lactation in women\n\n          -  Current medication that is known to interact with opioids\n\n          -  Known contraindications or hypersensitivity to opioids\n\n          -  Current opioid therapy\n\n          -  Chronic pain disorder requiring regular medication"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02101840", 
            "org_study_id": "043-2013"
        }, 
        "intervention": [
            {
                "arm_group_label": "Apo-Oxycodone CR\u00ae", 
                "description": "a single 40mg oral dose of the controlled release oxycodone formulation Apo-Oxycodone CR\u00ae", 
                "intervention_name": "Apo-Oxycodone CR\u00ae", 
                "intervention_type": "Drug", 
                "other_name": "Oxycodone"
            }, 
            {
                "arm_group_label": "OxyNEO\u00ae", 
                "description": "a single 40mg oral dose of the controlled release oxycodone formulation OxyNEO\u00ae", 
                "intervention_name": "OxyNEO\u00ae", 
                "intervention_type": "Drug", 
                "other_name": "Oxycodone"
            }, 
            {
                "arm_group_label": "OxyContin\u00ae", 
                "description": "a single 40mg oral dose of the controlled release oxycodone formulation OxyContin\u00ae", 
                "intervention_name": "OxyContin\u00ae", 
                "intervention_type": "Drug", 
                "other_name": "Oxycodone"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "a single oral dose of placebo prepared using gelatin capsules and lactose filler with identical looking study capsules as the oxycodone products", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Placebo"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Oxycodone"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Substance-Related Disorders", 
            "Prescription Drug Misuse", 
            "Analgesics, Opioid", 
            "Oxycodone", 
            "Randomized Controlled Trial", 
            "Cross-Over Studies", 
            "Placebo", 
            "Healthy Volunteers"
        ], 
        "lastchanged_date": "March 30, 2014", 
        "link": {
            "description": "The Centre for Addiction and Mental Health (CAMH) is the leading mental health and addictions research facility in Canada, and one of the largest in the world.", 
            "url": "http://www.camh.ca/en/research"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Toronto", 
                    "country": "Canada", 
                    "state": "Ontario", 
                    "zip": "M5S 2S1"
                }, 
                "name": "Centre for Addiction and Mental Health"
            }, 
            "investigator": [
                {
                    "last_name": "Beth Sproule, PharmD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Andrew Smith, MDCM", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Keyghobad Farid Araki, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "4", 
        "official_title": "Abuse Liability of Controlled-Release Oxycodone Formulations", 
        "overall_contact": {
            "email": "beth.sproule@camh.ca", 
            "last_name": "Beth Sproule, PharmD", 
            "phone": "416-535-8501", 
            "phone_ext": "36501"
        }, 
        "overall_official": {
            "affiliation": "Centre for Addiction and Mental Health", 
            "last_name": "Beth Sproule, PharmD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Change from Baseline on Visual Analogue Scale for \"Drug Liking\" Over 8 Hours After Drug Administration", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 1,1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, and 8 hours after drug administration"
            }, 
            {
                "measure": "Change from Baseline on Visual Analogue Scale for \"Drug High\" Over 8 Hours After Drug Administration", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 1,1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, and 8 hours after drug administration"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02101840"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Centre for Addiction and Mental Health", 
            "investigator_full_name": "Beth Sproule", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pupil Diameter", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 1,1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, and 8 hours after drug administration"
            }, 
            {
                "description": "Plasma oxycodone concentration", 
                "measure": "Cmax", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 6 hours post-administration"
            }, 
            {
                "measure": "Profile of Mood States (POMS)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 1,1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, and 8 hours after drug administration"
            }, 
            {
                "description": "Digit Symbol Substitution Test (DSST)", 
                "measure": "Psychomotor Performance", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 1,1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, and 8 hours after drug administration"
            }, 
            {
                "measure": "Visual Analogue Scale for \"Any Drug Effects\"", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 1,1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, and 8 hours after drug administration"
            }, 
            {
                "measure": "Visual Analogue Scale for \"Good Effects\"", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 1,1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, and 8 hours after drug administration"
            }, 
            {
                "measure": "Visual Analogue Scale for \"Bad Effects\"", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 1,1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, and 8 hours after drug administration"
            }, 
            {
                "measure": "Visual Analogue Scale for \"Feel Sick\"", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 1,1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, and 8 hours after drug administration"
            }, 
            {
                "measure": "Visual Analogue Scale for \"Nausea\"", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 1,1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, and 8 hours after drug administration"
            }, 
            {
                "measure": "Visual Analogue Scale for \"Sleepy\"", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 1,1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, and 8 hours after drug administration"
            }, 
            {
                "measure": "Visual Analogue Scale for \"Dizzy\"", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 1,1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, and 8 hours after drug administration"
            }, 
            {
                "description": "Addiction Research Center Inventory (ARCI)", 
                "measure": "Sedation", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 1,1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, and 8 hours after drug administration"
            }, 
            {
                "description": "Addiction Research Center Inventory (ARCI)", 
                "measure": "Euphoria", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 1,1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, and 8 hours after drug administration"
            }, 
            {
                "description": "Addiction Research Center Inventory (ARCI)", 
                "measure": "Dysphoric Changes", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 1,1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, and 8 hours after drug administration"
            }, 
            {
                "description": "Addiction Research Center Inventory (ARCI)", 
                "measure": "Psychotomimetic Changes", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 1,1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, and 8 hours after drug administration"
            }, 
            {
                "description": "Addiction Research Center Inventory (ARCI)", 
                "measure": "Somatic Disturbances", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 1,1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, and 8 hours after drug administration"
            }, 
            {
                "description": "Addiction Research Center Inventory (ARCI)", 
                "measure": "Sensory Disturbances", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 1,1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, and 8 hours after drug administration"
            }, 
            {
                "description": "Plasma oxycodone concentrations", 
                "measure": "Tmax", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 6 hours post drug administration"
            }
        ], 
        "source": "Centre for Addiction and Mental Health", 
        "sponsors": {
            "collaborator": {
                "agency": "University of Toronto", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Centre for Addiction and Mental Health", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}